Vanguard Group Inc. Purchases 330,553 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Vanguard Group Inc. increased its position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 13.1% in the 4th quarter, HoldingsChannel reports. The fund owned 2,846,473 shares of the company’s stock after acquiring an additional 330,553 shares during the period. Vanguard Group Inc. owned approximately 0.06% of Spyre Therapeutics worth $66,266,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. KLP Kapitalforvaltning AS acquired a new position in shares of Spyre Therapeutics during the fourth quarter worth $182,000. Teacher Retirement System of Texas acquired a new position in Spyre Therapeutics during the 4th quarter valued at about $242,000. Natixis Advisors LLC acquired a new position in Spyre Therapeutics during the 4th quarter valued at about $403,000. Swiss National Bank raised its stake in Spyre Therapeutics by 38.3% in the fourth quarter. Swiss National Bank now owns 68,600 shares of the company’s stock valued at $1,597,000 after buying an additional 19,000 shares during the last quarter. Finally, Candriam S.C.A. boosted its holdings in Spyre Therapeutics by 135.8% in the fourth quarter. Candriam S.C.A. now owns 247,591 shares of the company’s stock worth $5,764,000 after acquiring an additional 142,591 shares in the last quarter. Hedge funds and other institutional investors own 80.39% of the company’s stock.

Spyre Therapeutics Price Performance

NASDAQ SYRE opened at $11.93 on Friday. Spyre Therapeutics, Inc. has a 1 year low of $10.91 and a 1 year high of $40.84. The company has a market capitalization of $718.87 million, a PE ratio of -1.60 and a beta of 3.05. The company has a fifty day moving average of $18.69 and a 200 day moving average of $24.40.

Spyre Therapeutics (NASDAQ:SYRE) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.08. Research analysts expect that Spyre Therapeutics, Inc. will post -4.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on SYRE shares. The Goldman Sachs Group upgraded shares of Spyre Therapeutics to a “strong-buy” rating in a report on Tuesday, February 18th. Leerink Partners began coverage on shares of Spyre Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $45.00 price target for the company. Wolfe Research began coverage on shares of Spyre Therapeutics in a research note on Tuesday, March 18th. They set an “outperform” rating and a $27.00 price objective for the company. Wedbush restated an “outperform” rating and issued a $65.00 target price on shares of Spyre Therapeutics in a research note on Monday, January 13th. Finally, Leerink Partnrs raised Spyre Therapeutics to a “strong-buy” rating in a research report on Tuesday. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $49.57.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).